Tag:
Biogen Idec
Latest Headlines
Latest Headlines
Does pharma spend more on marketing than R&D? A numbers check
So, do drug companies really spend more money on marketing than on R&D? In the Pipeline takes a look at that contention, and the cold hard facts are these: Probably not. But it's hard to tell for sure.
Biotech Receptos claims $73M IPO prize to fuel oral MS contender
San Diego-based biotech Receptos has priced an initial public offering of 5.2 million shares at $14, raising $72.8 million as the company closes in on late-stage development of its lead candidate for multiple sclerosis.
Biogen's HQ plans change, thanks to early Tecfidera success
What happens when a new drug comes charging out of the launch gate? For Biogen Idec, it means a rethink of its real estate plans.
Fast-growing Biogen Idec bursts the seams at new Cambridge HQ
When George Scangos took the helm at Biogen Idec, he left little doubt that he couldn't much stand the company's gleaming new headquarters in Weston, MA, the brainchild of ex-CEO Jim Mullen. R&D in Cambridge was where it was at, and that's where he spent the bulk of his time.
Amid $2B in cost-cutting, Teva sales suffer from generic erosion
Teva Pharmaceutical Industries may be a generics behemoth, but its earnings this quarter bore a more-than-casual resemblance to Big Pharma's.
Martin Leach's 16-year interview for the job of Big Data boss at Biogen Idec
Martin Leach has spent the past several months building a new data sciences group at Biogen Idec, where his team of informatics and tech pros has undertaken the sizable task of enabling scientists and others at the biotech powerhouse to make use of Big Data.
UPDATED: Biogen CEO Scangos scores 19% pay hike during stellar 2012
Biogen Idec CEO George Scangos took home one of the largest pay packages in the biotech industry in 2012--a total of $13.45 million in 2012, a 19% jump in pay from his $11.33 million pay package the previous year, the Weston, MA-based company reported Monday in a proxy statement.
Atlas Venture targets early-stage biotech bets with new $265M fund
After a period of revamping a venture strategy gone wrong, Atlas Venture has come out today with news about an oversubscribed 9 th fund of $265 million. It's a rare comeback story in a VC industry that is suffering from an overall lack of capital to fuel startups in biotech and other high-risk-and-reward sectors.
UPDATED: Fujifilm expands former Merck biologics plant in U.K.
Fujifilm has opened a cell-banking facility at the former Merck plant in Billingham, U.K., and is also expanding its mammalian cell manufacturing capacity.
Biogen Idec, big biotechs trounce pharma players on multiple fronts this decade
A new analysis shows that the biggest biotech players have outperformed a group of pharma giants over the previous three years, with the value of the biotech group up 57% compared with 17.4% growth in the pharma camp.
